The ASX 200 has been trading flat, with sectors like Financials and Real Estate performing well while Materials and IT stocks have faced challenges. Despite the somewhat stagnant market conditions, penny stocks continue to attract attention as potential investment opportunities. Though often seen as speculative, these smaller or newer companies can offer significant value when backed by strong financials, making them intriguing options for investors seeking hidden gems in the market.

Top 10 Penny Stocks In Australia

Name Share Price Market Cap Financial Health Rating EZZ Life Science Holdings (ASX:EZZ) A$2.31 A$108.97M ★★★★★★ GTN (ASX:GTN) A$0.615 A$117.37M ★★★★★★ IVE Group (ASX:IGL) A$2.72 A$419.37M ★★★★★☆ West African Resources (ASX:WAF) A$2.19 A$2.5B ★★★★★★ Southern Cross Electrical Engineering (ASX:SXE) A$1.71 A$452.14M ★★★★★★ Tasmea (ASX:TEA) A$3.19 A$751.63M ★★★★★☆ Regal Partners (ASX:RPL) A$2.11 A$709.31M ★★★★★★ Lindsay Australia (ASX:LAU) A$0.69 A$218.85M ★★★★☆☆ Bisalloy Steel Group (ASX:BIS) A$3.26 A$154.69M ★★★★★★ CTI Logistics (ASX:CLX) A$1.735 A$139.74M ★★★★☆☆

Click here to see the full list of 1,008 stocks from our ASX Penny Stocks screener.

Let's take a closer look at a couple of our picks from the screened companies.

AnteoTech

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: AnteoTech Limited is engaged in the development, manufacturing, commercialization, and distribution of products for clean energy technology and life science markets across various regions including Australia, Asia, Europe, North America, and Latin America; it has a market cap of A$35.17 million.

Operations: AnteoTech generates revenue through the development of its intellectual property, with a reported amount of -A$0.55 million.

Market Cap: A$35.17M

AnteoTech Limited, with a market cap of A$35.17 million, is pre-revenue and currently unprofitable, generating less than US$1 million in revenue. Despite its financial challenges, the company has more cash than debt and short-term assets exceeding liabilities. Recent leadership changes include the appointment of Ms. Merrill Gray as Interim CEO to advance product commercialization in clean energy and life sciences markets. The stock's volatility has increased over the past year, reflecting uncertainty but also potential for growth if strategic initiatives succeed under new leadership amidst a volatile share price environment.

Navigate through the intricacies of AnteoTech with our comprehensive balance sheet health report here. Assess AnteoTech's previous results with our detailed historical performance reports.ASX:ADO Debt to Equity History and Analysis as at Jun 2025

EZZ Life Science Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Story Continues

Overview: EZZ Life Science Holdings Limited is involved in the formulation, production, marketing, and sale of health and wellbeing products across Australia, New Zealand, Mainland China, and internationally with a market cap of A$108.97 million.

Operations: The company's revenue is primarily generated from Company Owned products, contributing A$71.78 million, and Brought in Lines, which add A$3.26 million.

Market Cap: A$108.97M

EZZ Life Science Holdings, with a market cap of A$108.97 million, has demonstrated robust financial health and growth potential. The company reported significant earnings growth of 159.7% over the past year, surpassing industry averages. It maintains a strong balance sheet with short-term assets exceeding both short and long-term liabilities, and it operates debt-free, eliminating concerns about interest coverage or cash flow constraints. EZZ's high return on equity of 37.5% underscores its operational efficiency while trading at a substantial discount to its fair value suggests attractive valuation prospects for investors seeking opportunities in the life sciences sector.

Click here and access our complete financial health analysis report to understand the dynamics of EZZ Life Science Holdings. Explore EZZ Life Science Holdings' analyst forecasts in our growth report.ASX:EZZ Revenue & Expenses Breakdown as at Jun 2025

XRF Scientific

Simply Wall St Financial Health Rating: ★★★★★★

Overview: XRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries across Australia, Canada, and Europe with a market cap of A$240.32 million.

Operations: The company's revenue is derived from three main segments: Consumables (A$18.86 million), Precious Metals (A$21.48 million), and Capital Equipment (A$22.20 million).

Market Cap: A$240.32M

XRF Scientific Limited, with a market cap of A$240.32 million, presents a compelling profile within the penny stock landscape due to its stable financial footing and growth trajectory. The company has shown consistent earnings growth, averaging 22.8% annually over the past five years, although recent growth slowed to 11.7%. Its seasoned management and board contribute to strategic stability. Financially prudent, XRF's short-term assets significantly exceed liabilities, and it maintains more cash than total debt, ensuring robust liquidity. Trading below estimated fair value enhances its appeal for investors seeking undervalued opportunities in the scientific and industrial sectors.

Take a closer look at XRF Scientific's potential here in our financial health report. Gain insights into XRF Scientific's future direction by reviewing our growth report.ASX:XRF Financial Position Analysis as at Jun 2025

Key Takeaways

Click this link to deep-dive into the 1,008 companies within our  ASX Penny Stocks screener. Ready For A Different Approach? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:ADO ASX:EZZ and ASX:XRF.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments